ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
| Pharmaceuticals Industry | Healthcare Sector | Robert Ford CEO | XSGO Exchange | US0028241000 ISIN |
| US Country | 114,000 Employees | 15 May 2026 Last Dividend | 2 Jan 2013 Last Split | 13 Jan 1978 IPO Date |
Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.
Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains: